3H11 treatment reduced the CD62L+ KC population (Fig. 8e) and suppressed NET formation in the liver (Fig. 8f), leading to mitigation of metastatic growth of cancer and alleviation of metastatic burden (Fig. 8g, h). This evidence concerns the gene SELL and cancer.